The COVID-19 pandemic dramatically accelerated cancer-vaccine science by validating the mRNA technology at global scale.
Anaïs Frappé
Advertisement
Anaïs Frappé is a Partner at Windrose Consulting Group in London.
Articles by Anaïs Frappé
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Removes Two Study Requirement for New Drug Approval Process: Report
2
BioNTech Files Suit Against Moderna for Patent Infringement
3
The Emergence of Cancer Vaccines: Reframing Value Demonstration, Pricing, and Access
4
How FDA's Action Against Non-FDA-Approved GLP-1 Products Affects the Competitive Landscape
5